On behalf
of AMP T2D, the DCC aggregates data, automates analysis, and communicates results relevant to the genetics of type 2 diabetes and related traits, and supports collaboration within the AMP T2D Project.
Not exact matches
AMP T2D aims to make pre-competitive data, analyses, and research resources accessible and useful to the biomedical community, and to conduct studies to determine the functions
of relevant variants and the mechanisms by which they may contribute to disease.
AMP T2D focuses on type 2 diabetes genetics, seeking to use and supplement the substantial amount
of human genetic data available from people with type 2 diabetes, or at risk
of developing it, to identify and validate novel molecules and pathways as targets for therapeutic development.
The
AMP type 2 diabetes (
AMP T2D) consortium is a collaboration
of a number
of AMP funded investigators from around the world, including the Broad Institute, University
of Michigan, University
of Oxford, and the European Biomedical Institute.